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Abstract 
Background: Neuroendocrine tumors (NETs), as a rare and heterogeneous category of solid tumors, feature various 
morphologies and behaviors. In recent years, the incidence of NETs has continued to increase. Endoscopic mucosal 
resection (EMR) is one of the therapeutic modalities for the treatment of gastric and rectal NETs.
Methods: We evaluated patients with well-differentiated NETs of the stomach, duodenum, or rectum between 2011 
and 2018. In this study, all cases with tumors confined to the mucosal or submucosal layers and smaller than 20 mm 
were resected using the EMR technique. We used EUS, CT scan, or MRI to exclude patients with advanced disease. All 
patients were actively monitored for recurrence according to the recommended protocols.
Results: A total of 36 patients with NETs entered the study; 17 (47.2%) were female and the remaining 19 (52.8%) 
were male, with a total age range of 20–74 years (mean: 52.47 ± 13.47 years). Among the tumors, 31 cases (86.1%) 
were G1 and the remaining 5 (13.9%) were G2. Based on the pathology reports, 22 tumors (61.1%) were smaller than 
1 cm, while the remaining 14 (38.9%) were between 1–2 cm. Twenty-two patients (61.1%) had a margin of specimen 
involved with the tumor. No recurrence was observed during the mean follow-up time of 63.5 ± 19.8 months (range: 
39–103 months). All 36 cases survived during the study period.
Conclusion: Conventional EMR procedure provides low chance of R0 (complete resection) achievement in gastroin-
testinal NETs smaller than 20 mm and limited to the mucosa or sub mucosa. However, it could be an option if patients 
are closely followed. Postoperative marginal involvement is not a reliable predictor of disease recurrence, which may 
be explained by the deleterious effect of heat coagulation and cauterization applied during tumor removal.
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Introduction
Gastrointestinal neuroendocrine tumors (NETs), called 
carcinoid tumors, feature a wide spectrum of malignant 
potential and originate from enterochromaffin-like (ECL) 
cells. Gastric NETs involve 7 to 8% of all neuroendocrine 
tumors and are classified into three main types. The 
first type accounts for 75% of patients and is associ-
ated with chronic atrophic gastritis [1, 2], while the sec-
ond accounts for 6% of cases and is linked with multiple 
endocrine neoplasm (MEN) disease (including Zollinger-
Ellison syndrome) and the third is the most invasive type 
with a high chance of metastasis [3, 4].
In recent years, the prevalence of gastrointestinal 
NETs has increased such that in 2004, the incidence of 
NETs was 5.25 per 100,000 population, while in 1973, 
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this rate was only 1.09 cases per 100,000 [1–3]. Despite 
the increase in the prevalence and detection of NETs, 
significant improvements in overall survival have been 
observed, which might be due to greater awareness of 
NETs and improvements in medical imaging and endos-
copy [5]. Endoscopic mucosal resection (EMR) and 
endoscopic sub mucosal dissection (ESD) are the two 
endoscopic techniques used to treat NETs. The EMR 
technique is a relatively simple technique requiring unso-
phisticated skills and inexpensive tools. This technique is 
used for well-differentiated gastric or duodenal lesions 
smaller than 20  mm in diameter and well-differentiated 
tumors confined to the mucosal layer without invasion 
to the lymph nodes or blood vessels. Similar to the NETs 
of the upper gastrointestinal tract, those confined to the 
rectum may be amenable to endoscopic removal. NETs of 
the rectum that are smaller than 10 mm in diameter are 
typically confined to the submucosal layer. These small 
tumors are usually not invasive; therefore, they are good 
candidates for colonoscopic removal by EMR or ESD. 
The incomplete removal of the tumoral lesion, as one of 
the essential causes of recurrence, is among the high risks 
accompanied by the EMR procedure. Hence, the ESD 
technique is more favored as it diminishes the chance of 
incomplete excision. Besides, ESD enables the complete 
excision of the lesion both vertically and peripherally 
within an en bloc sample, which permits a more accurate 
pathological evaluation. Nonetheless, ESD takes a longer 
amount of time and requires more sophisticated skills 
and increased resources [6–9].
This study was designed to address the long-term fol-
low-up of cases with localized NETs in either rectum 
or upper gastrointestinal (GI) tract who were treated by 
EMR procedure.
Patients and methods
This study was conducted at Shiraz University of Medi-
cal Sciences in accordance with relevant guidelines and 
regulations. After obtaining study approval from the eth-
ics committee of Shiraz University of Medical Sciences 
(IR.SUMS.MED.REC.1397.110), all cases with patho-
logical confirmation of NET (either with biopsy or after 
resection) from October 2011 through March 2018 were 
entered into the study. Patients with advanced tumors 
unfit for endoscopic removal (larger than 2  cm in size,, 
invasion of muscularis properia on endoscopic ultra-
sound [EUS], and/or poorly differentiated lesions) were 
excluded, as well as those with non-gastrointestinal 
involvement, non-endoscopic tumor excision, inability 
to obtain the desired information, and/or lost on follow-
up. Informed consent was obtained from all patients 
and the option of surgery was made to all cases with 
margin involvement, particularly to those with NET in 
the duodenum.
In the beginning, EUS was conducted using a radial 
array echoendoscope for all patients with gastroduode-
nal and rectal lesions for precise local staging prior to 
resection. Then, cases with lesions limited to the mucosa 
or submucosa and less than 2 cm in diameter were con-
sidered for EMR. In this study we did not excluded cases 
with size up to 2 cm if there was no lymph node metas-
tasis or invasion to muscularis propria (MP) based on 
pre resection endosonography findings. After conscious 
sedation under the supervision of an anesthesiologist, 
EMR was performed with either snare polypectomy 
after submucosal saline injection or via the band ligation 
method based on the gastroenterologist’s preference and 
the size/location of the tumor. In all of patients at the 
time of endoscopic resection any visualized remnant tis-
sue was cauterized with the tip of snare. A CT scan, MRI, 
and/or Octreoscan was employed when appropriate to 
evaluate the disease extent and distant metastasis accord-
ing to the relevant guidelines [9–12]. After resecting 
the lesion, follow-up program consisted of endoscopic 
examinations at three, six, and twelve month intervals. In 
those with incomplete resection follow-up pursued at six 
to twelve month intervals, thereafter. Either CT scan or 
MRI was performed at 12-month intervals. During fol-
low-up endoscopic examinations defoaming agent Sime-
thicone was applied for thorough and clear visualization. 
NBI was applied in order to increase the yield of study. 
Biopsy was taken from any suspected lesion. At the time 
of data collection, all cases were recalled and reevalua-
tion for survival and tumor recurrence was meticulously 
performed. Tumors were classified according to the 2010 
World Health Organization classification based on the 
assessment of mitotic rate and/or Ki-67 index [13]. All 
pathologic reports were reviewed and appropriate infor-
mation including the size of the lesion, grading, and mar-
gin clearance (R0) status was recorded.
Statistical analysis
Statistical Package for the Social Sciences Version 19.0 
(SPSS Inc., Chicago, IL, USA) was used to analyze the 
data. Frequency (%) and mean ± standard deviation were 
also used as descriptive statistics.
Results
Forty-four cases with definite pathologic diagno-
sis of NET were evaluated in this study. Six patients 
underwent surgical resection due to having tumors 
with a high grade (G3), unsuitable location (ileum), 
or advanced stage (> T1). Furthermore, two cases 
were lost during follow-up. Table  1 demonstrates 
the demographic data and clinical features of NETs. 
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Ultimately, 36 patients entered the study; seventeen 
(47.2%) were female and the remaining 19 (52.8%) 
were male, with, a total age range of 20–74  years 
(mean: 52.47 ± 13.47  years). Fifteen tumors (41.7%) 
were located in the stomach, 12 (33.3%) in the duode-
num, and 9 (25%) in the rectum. Of these, 31 tumors 
(86.1%) were G1 and the remaining 5 tumors (13.9%) 
were G2. Based on the pathology report, 22 tumors 
(61.1%) were smaller than 1  cm in diameter while 14 
(38.9%) were between 1–2  cm. Only 4 patients were 
treated with modified EMR (i.e. cap or suction assisted 
EMR) and all of them had no resection margin involve-
ment. All of them were below 1 cm.Twenty-two (61.1%) 
patients had a margin of specimen involved with 
the tumor. Out of the tumors with positive margins, 
69.6% were smaller than 1 cm and 30.4% were between 
1–2  cm. No case with lymphovascular invasion was 
reported in pathological specimens. Table  2 summa-
rizes the tumor margin involvement status based on 
different primary tumor locations and sizes. No recur-
rence was observed during the mean follow-up time of 
63.5 ± 19.8 months (range: 39–103 months). The mean 
follow-up in patients with sample margin involvement 
was 56.7 ± 17.8  months (range: 39–97  months), com-
pared with 74.2 ± 18.4 months (range: 42–103 months) 
among patients with sample margin clearance. All 
36 cases undergoing EMR survived during the study 
period. One patient in the surgical group died due to 
cardiovascular disease and senility.
Discussion
Neuroendocrine tumors encompass a heterogeneous 
group of malignancies capable of secreting certain hor-
mones and amines. In western countries, the annual inci-
dence and prevalence of NETs have been calculated as 
3.56 per 100,000 and 48 per 100,000 individuals, respec-
tively. In the past several decades, these tumors have 
been increasingly recognized, which is thought to be due 
to increased awareness of NETs and the advent of sophis-
ticated radiological modalities. Concurrently, early detec-
tion and potent therapeutic options have led to improved 
survival of patients with NETs. These tumors are clas-
sified into well-differentiated or poorly differentiated 
groups based on pathological morphology, mitotic rate, 
and the Ki-67 index. Accordingly, tumors are designated 
as G1, G2, or G3 [12, 14, 15].
Conventional polypectomy, EMR, and ESD are con-
sidered as therapeutic endoscopic modalities for treating 
gastric, duodenal, and rectal NETs with limited penetra-
tion into the submucosa [15]. Conventional polypectomy 
using a snare is a simple procedure. Although few stud-
ies showed that polypectomy might yield a high degree 
of free resection margins in small and superficial NETs, 
most of these tumors have already penetrated the sub-
mucosa, which may lead to decreased curability of con-
ventional polypectomy [16, 17]. EMR can be performed 
with or without a cap or ligation device. It is a relatively 
simple procedure with a rapid learning curve and much 
less utilization of resources than ESD. EMR may achieve 
complete pathological resection in 52% to 84.6% of NETs 
[18, 19]. On the other hand, ESD requires sophisticated 
equipment and increased expertise. The major advantage 
of ESD is its capability to achieve a better lateral and ver-
tical resection margin at the expense of a much greater 
Table 1 Demographic characteristics and clinical features of 
patients with neuroendocrine tumors (NETs)
Number of patients 36
Male sex, n (%) 19 (52.8%)
Female sex, n (%) 17 (47.2%)
Age, years [mean (range)] 52.47 ± 13.47 (20–74)
Location of tumor
 Stomach 15(41.7%)
 Duodenum 12 (33.3%)
 Rectum 9 (25%)
WHO tumor grade
 G1 31 (86.1%)
 G2 5 (13.9%)
Tumor size
  < 1 cm 22(61.1%)
 1–2 cm 14 (38.9%)
Resection margin
 Involved 22(61.1%)
 Free 14 (38.9%)
Follow-up, month [mean (range)]
 All patients with EMR 63.5 ± 19.8
 Patients with free resection margin 74.2 ± 18.4
 Patients with involved resection margin 56.7 ± 17.8
Table 2 Tumor margin involvement status based on different 
tumor primary locations and sizes
Tumor margin involvement Tumor size
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risk of bleeding or perforation [20]. Sato et al. showed in 
a low number of cases that about 66% of NETs resected 
by EMR had a positive vertical margin, whereas no case 
with ESD had positive vertical or horizontal margins [21].
In this study, we performed EMR for the resection of 
all GI NETs even larger than 1 cm ( up to maximum sizes 
of 2 cm in diameter) if there was no evidence of invasion 
to muscularis propria (MP) and no lymph node enlarge-
ment based on pre resection endosonographic findings. 
The management of intermediate-sized NETs (between 
1-2 cm) confined to mucosa or submucosa is somewhat 
controversial. Other than tumor size and depth, addi-
tional factors including mitotic index and lymphovascu-
lar invasion could notoriously affect patients prognosis 
[22–24]. Some previous studies have shown that gastric 
NET up to 2 cm are amenable to endoscopic resection [1, 
25–27]. While involvement of MP should be considered 
a contraindication for local resection at least with EMR, 
the size up to 2  cm may still response to local resec-
tion. In our study, out of 14 (38.9%) cases who had NETs 
between 1-2  cm, six (42.8%) patients did not achieved 
complete resection after EMR. However, none of them 
experienced a recurrence. As a result, our findings show 
that EMR could be conducted in NET between 1–2 cm 
if there is no lymphovascular invasion or involvement 
of MP. In our study, the majority of tumors were G1 
and smaller than 1  cm. However, despite the reports of 
similar studies, about 61% of our cases failed to achieve 
a clear resection margin after EMR. Out of 22 tumors 
with incomplete resection, 14 (63.6%) were located in the 
duodenum and rectum. Out of 16 tumors less than 1 cm 
in size and positive margin after resection, 56.2% were 
located in the duodenum and rectum. Presumably, both 
difficulty in EMR within the duodenum and more con-
servative approaches implemented by physicians to avoid 
complications during EMR in the rectum and duodenum 
are factors leading to the higher number of tumors with 
incomplete resection despite smaller sizes. Several stud-
ies on rectal NETs showed that the complete resection 
rate was significantly higher after ESD relative to simple 
EMR but was comparable to modified EMR (EMR with 
banding or using a cap and suction) [19, 28]. Surprisingly, 
other studies, including a meta-analysis on 14 studies and 
823 cases, concluded that modified EMR with the suction 
method (93.65%) is superior to ESD (84.08%) in achiev-
ing free resection margins in rectal NETs smaller than 
10 mm [29–31]. The modified EMR (m-EMR) technique 
using either suction cap or ligation band is much more 
effective in achieving complete resection and R0 margin 
comparing to conventional EMR procedure which is per-
formed by a snare after submucosal saline injection [19]. 
In our study, only 4 patients were treated with m-EMR 
procedure. All of these cases achieved complete resection 
(R0). On the other hand, conventional EMR procedure 
was implemented in the remaining 32 cases. As a result 
of high number of conventional EMR procedures done 
we could only achieve a 40% complete resection rate 
based on histology.
In this study, cases with positive resection margins 
were meticulously followed according to recommended 
guidelines and no further resections were undertaken. 
We followed all cases with either border involvement 
or free resection margins for approximately 5 years. On 
follow-up, no case with tumor recurrence was detected 
despite a high margin involvement rate among our 
patients. This is in concordance with the series reported 
by Weili Sun et  al., who achieved complete resection in 
31 out of 41 (75.6%) with EMR and 30 out of 35 (85.7%) 
cases with ESD. Interestingly, in those 14 cases with posi-
tive resection margins, they merely followed the patients 
and no recurrence was reported [20]. It is presumed that 
the electrocauterization effect with heat generation may 
destruct the remnant of malignant cells and preclude 
tumor relapse despite margin involvement in the patho-
logical specimen. Furthermore, in our study, most of the 
resected tumors with border involvement after resection 
were smaller than 10 mm, increasing the chance of tumor 
cell degeneration with electrocauterization.
In this series, there was no instance of perforation or 
major bleeding. However, this might be due to the char-
acteristics of the patients and expertise of the perform-
ers, so it could not be generalized.
The strong point of this study was its long-lasting fol-
low-up of patients with an acceptable number of cases 
compared to similar small studies. However, despite the 
remarkable results, this study still has several limitations. 
First, this work was a retrospective study that may be 
associated with the risk of selection bias. Furthermore, 
this study is categorized as a single-center case series 
without comparison with ESD or modified EMR.
In conclusion, conventional EMR procedure provides 
low chance of R0 (complete resection) achievement 
in gastrointestinal NETs smaller than 20  mm and lim-
ited to the mucosa or sub mucosa, but still EMR could 
be an option in low grade lesions up to 20 mm without 
lymph node metastasis or invasion to muscularis pro-
pria if patients are closely followed. Whenever EMR is 
performed, particularly where and when equipment, 
instruments, or adequate expertise for ESD are not read-
ily accessible, incomplete resection of the lesion is not 
relevant for the prognosis of these patients and tumor 
recurrence, especially when cauterization of the margins 
of the lesion is done to ablated the residual tumor. This 
latter result is very interesting and might be topic for a 
different study.
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